Skip to main content

Advertisement

SpringerLink
Log in

Review of medical and surgical management of Clostridium difficile infection

  • Review
  • Published:
Techniques in Coloproctology Aims and scope Submit manuscript

Abstract

Clostridium difficile infection (CDI) has become an important area in our daily clinical practice. C. difficile is known to cause a broad spectrum of conditions ranging from asymptomatic carriage, through mild or moderately severe disease with watery diarrhoea, to the life-threatening pseudomembranous colitis (PMC), with toxic megacolon and ileus. Peoples who have been treated with broad-spectrum antibiotics, patients with serious underlying co-morbidities and the elderly are at greatest risk. Over 80% of CDIs reported are in people aged over 65. Due to the alarming increase in its frequency, appearance of more virulent strains and occasional need for life-saving surgical intervention, a more coherent multidisciplinary approach is needed. Combination of rapid turn round time and accurate diagnosis will result in a better management of CDI and a timely implementation of infection control measure. Discontinuation of causative agents such as antibiotic treatment is often curative. In more serious cases, oral administration of metronidazole or vancomycin is the treatment of choice. Relapses of CDI have been reported in about 20–25% of cases, this may increase to 45–60% after the first recurrence. Patients should be treated as soon as possible when the diagnosis of Clostridium difficile colitis is made to avoid sepsis or bowel perforation. Colectomy may improve the outcome of the patient with systemic or complicated Clostridium difficile colitis. This article reviews the changing epidemiological picture, microbiology, histopathology and both medical and surgical managements.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aslam S, Hamill RJ, Musher DM (2005) Treatment of Clostridium difficile associated disease: old therapies and new strategies. Lancet Infect Dis 5:549–557

    CAS  PubMed  Google Scholar 

  2. McFarland LV, Mulligan ME, Kwok RY, Stamm WE (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320:204–210

    CAS  PubMed  Google Scholar 

  3. Hall IC, O’Toole E (1935) Intestinal flora in newborn infants with a description of a new pathogenic anaerobe: Bacillus difficilis. Am J Dis Child 48:390–402

    Google Scholar 

  4. McFarland LV, Brandmarker SA, Guandalini S (2000) Pediatric Clostridium difficile: a phantom menace or clinical reality? J Pediatr Gastroenterol Nutr 31:220–231

    CAS  PubMed  Google Scholar 

  5. Riggs MM, Sethi AK, Zabarsky TF et al (2007) Asymptomatic carriers are a potential source for transmission of epidemic and non-epidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 45:992−998

    PubMed  Google Scholar 

  6. Kyne L, Warny M, Qamar A, Kelly CP (2000) Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342:390−397

    CAS  PubMed  Google Scholar 

  7. Sunenshine RH, McDonald LC (2006) Clostridium difficile-associated disease: new challenges from an established pathogen. Cleveland Clinic J Med 73:187−197

    Google Scholar 

  8. Hurley BW, Nguyen CC (2002) The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhoea. Arch Intern Med 162:2177–2184

    PubMed  Google Scholar 

  9. Kyne L, Hamel MB, Polavaram R, Kelly CP (2002) Healthcare costs and mortality associated with nosocomial diarrhoea due to Clostridium difficile. Clin Infect Dis 34:346–353

    PubMed  Google Scholar 

  10. Wilcox MH (2003) Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol 17:475–493

    PubMed  Google Scholar 

  11. Wilson KH (1993) The micro ecology of Clostridium difficile. Clin Infect Dis 16:214–218

    Google Scholar 

  12. Kelly CP, Pothoulakis C, LaMont JT (1994) Clostridium difficile colitis. N Engl J Med 330:257–262

    CAS  PubMed  Google Scholar 

  13. Monaghan T, Boswell T, Mahida YR et al (2008) Recent advances in Clostridium difficile-associated disease. Gut 57:850–860

    CAS  PubMed  Google Scholar 

  14. Bignardi GE (1998) Risk factors for Clostridium difficile infection. J Hosp Infect 40:1–15

    CAS  PubMed  Google Scholar 

  15. Ricciardi R, Ogilvie JW, Roberts PL, Marcello PW, Concannon TW, Baxter NN (2009) Epidemiology of Clostridium difficile Colitis in hospitalised patients with inflammatory bowel disease. Dis Colon Rectum 52:40–45

    PubMed  Google Scholar 

  16. Tonna I, Welsby PD (2005) Pathogenesis and treatment of Clostridium difficile infection. Postgrad Med J 81:367–369

    CAS  PubMed  Google Scholar 

  17. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN (2008) A case–control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 62:388–396

    CAS  PubMed  Google Scholar 

  18. Aseeri M, Schroeder T, Kramer J et al (2008) Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile associated diarrhoea in hospitalised patients. Am J Gastroenterol 103:2308–2313

    PubMed  Google Scholar 

  19. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S (2008) Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 179:767–772

    PubMed  Google Scholar 

  20. Leonard J, Marshall JK, Moayyedi P (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 102:2047–2056

    PubMed  Google Scholar 

  21. Lowe D, Mamdani MM, Kopp A, Low DE, Juurlink DN (2006) Proton pump inhibitors and hospitalisation for Clostridium difficile associated disease: a population-based study. Clin Infect Dis 43:1272–1276

    CAS  PubMed  Google Scholar 

  22. Hermsen JL, Dobrescu C, Kudsk KA (2008) Clostridium difficile: a surgical disease in evolution. J Gastrointest Surg 12:1512–1517

    PubMed  Google Scholar 

  23. McFarland LV (2008) Update on the changing epidemiology of Clostridium difficile—associated disease. Nature Clin Pract 5:40–48

    Google Scholar 

  24. Burke GW, Wilson ME, Mehrez IQ (1988) Absence of diarrhoea in toxic megacolon complicating Clostridium difficile pseudomembranous colitis. Am J Gastroent 83:304–307

    CAS  PubMed  Google Scholar 

  25. Viswanath YK, Griffith CD (1990) Role of surgery in antibiotic induced pseudomembranous colitis. Am J Surg 160:535–539

    Google Scholar 

  26. Bartlett JG (1990) Clostridium difficile: clinical considerations. Rev Infect Dis 12:S243–S251

    PubMed  Google Scholar 

  27. Bartlett JG (2002) Clinical practice: antibiotic-associated diarrhea. N Eng J Med 346:334–339

    Google Scholar 

  28. Clostridium difficile infection (2008) How to deal with the problem, a board to ward approach. Department of Health Steering Group on Healthcare Associated Infection. Department of Health; Gateway Reference 9833

  29. Diagnosis, Treatment, and Management of CDI (2008) An Expert Interview with Cassandra D. Salgado, MD, MS. Medscape Infectious Diseases. http://www.medscape.com/viewarticle/576542

  30. Pépin J, Valiquette L, Cossette B (2005) Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hyper virulent strain in Quebec. CMAJ 173:1037–1042

    PubMed  Google Scholar 

  31. McDonald LC, Kilgore GE, Thompson A et al (2005) An epidemic, toxin gene variant strain of Clostridium difficile. N Engl J Med 353:2433–2441

    CAS  PubMed  Google Scholar 

  32. Matamouros S, England P, Dupuy B (2007) Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 64:1274–1288

    CAS  PubMed  Google Scholar 

  33. Cloud J, Kelly CP (2007) Update on Clostridium difficile associated disease. Cur Opin Gastroenterol 23:4–9

    Google Scholar 

  34. Kuijper EJ, van Dissel JT, Wilcox MH (2007) Clostridium difficile: changing epidemiology and new treatment options. Cur Opin Infect Dis 20:376–383

    Google Scholar 

  35. Hubert B, Loo VG, Bourgault AM et al (2007) A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile associated disease in Quebec. Clin Infect Dis 44:238–244

    CAS  PubMed  Google Scholar 

  36. Warny M, Pepin J, Fang A et al (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079–1084

    CAS  PubMed  Google Scholar 

  37. Brazier JS, Raybould R, Patel B et al (2008) Distribution and antimicrobial susceptibility patterns of Clostridium difficile PCR ribotypes in English hospitals, 2007–08. Euro Surveill 13:1–4

    Google Scholar 

  38. Goorhuis A, Bakker D, Corver J et al (2008) Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 47:1162–1170

    CAS  PubMed  Google Scholar 

  39. Wilcox MH, Cunniffe JG, Trundle C, Redpath C (1996) Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 34:23–30

    CAS  PubMed  Google Scholar 

  40. Somaiah A, Blencowe N, PYE G, West R (2009) Clostridium difficile: how much do hospital staff know about it. Ann R Coll Surg Engl 91:464–469

    Google Scholar 

  41. Deaths involving Clostridium difficile; England and Wales, 2003-2007 (2008) Health Stat Q:67–76

  42. Jabbar A, Wright RA (2003) Gastroenteritis and antibiotic-associated diarrhoea. Prim Care 30:63–80

    PubMed  Google Scholar 

  43. Kyne L, Farrel RJ, Kelly CP (2001) Clostridium difficile. Gastroenterol Clin North Am 30:753–777

    CAS  PubMed  Google Scholar 

  44. Guerrant RL, Van Gilder T, Steiner TS et al (2001) Practice guidelines for the management of infectious diarrhoea. Clin Infect Dis 32:331–351

    CAS  PubMed  Google Scholar 

  45. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr (1995) Clostridium difficile-associated disease diarrhoea and colitis. Infect Control Hosp Epidemiol 16:459–477

    CAS  PubMed  Google Scholar 

  46. Blossom DB, McDonald LC (2007) The challenges posed by re-emerging Clostridium difficile infection. Clin Infect Dis 45:222–227

    PubMed  Google Scholar 

  47. NHS Purchasing and Supply Agency, Centre for Evidence-based Purchasing (CEP) (2008) Evaluation Report on Clostridium difficile toxin detection assays. CEP08054

  48. Fenner L, Widmer AF, Goy G et al (2008) Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. Clin Microbiol 49:328–330

    Google Scholar 

  49. Finney JMT (1990) Gastro-enterostomy for cicatrising ulcer of the pylorus. Bull John Hopkins Hospital 4:53–55 (1893) (cited by Bartlett JG. Clostridium difficile: clinical considerations. Rev Infect Dis 12:S243-S251)

  50. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB (1978) Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298:531–534

    Article  CAS  PubMed  Google Scholar 

  51. Chen FCS, Woods R (1994) Pseudomembranous pan-enteritis and septicaemia in a patient with ulcerative colitis. ANZ J of Surg 66:565–567

    Google Scholar 

  52. Morris LL, Villalba MR, Glover JL (1994) Management of pseudomembranous colitis. Am Surg 60:548–551

    CAS  PubMed  Google Scholar 

  53. Goulston SJM, McGovern VJ (1965) Pseudomembranous colitis. Gut 6:207–212

    Google Scholar 

  54. Price AB, Davies DR (1977) Pseudomembranous colitis. J Clin Pathol 30:1–12

    CAS  PubMed  Google Scholar 

  55. Yafi FA, Selvasekar CR, Cima RR (2008) Clostridium difficile enteritis following total colectomy. Tech Coloproctol 12:73–74

    CAS  PubMed  Google Scholar 

  56. Borriello SP (1998) Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 41:13–19

    CAS  PubMed  Google Scholar 

  57. Tedesco FJ (1979) Antibiotic associated pseudomembranous colitis with negative proctosigmoidoscopy examination. Gastroenterology 77:295–297

    CAS  PubMed  Google Scholar 

  58. Triadafilopoulos G, Hallstone AE (1991) Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology 101:685–691

    CAS  PubMed  Google Scholar 

  59. Spencer RC (1998) Clinical impact and associated costs of Clostridium difficile associated disease. J Antimicrob Chemother 41:5–12

    CAS  PubMed  Google Scholar 

  60. Dallal RM, Harbrecht BG, Boujoukas AJ et al (2002) Fulminant Clostridium difficile: an under appreciated and increasing cause of death and complications. Ann Surg 235:363–372

    PubMed  Google Scholar 

  61. Mallavarapu RK, Katner HP (2007) Clostridium difficile—associated diarrhoea and colitis in the hospitalised patient. Hosp Physician 21–27

  62. Kyne L, Farrell RJ, Kelly CP (2001) Clostridium difficile. Gastroenterol Clin North 30:753–777

    CAS  Google Scholar 

  63. Poutanen SM, Simor AE (2004) Clostridium difficile-associated diarrhoea in adults. CMAJ 171:51–58

    PubMed  Google Scholar 

  64. Tedesco FJ, Corless JK, Brownstein RE (1982) Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study. Gastroenterology 83:1259–1260

    CAS  PubMed  Google Scholar 

  65. Wanahita A, Goldsmith EA, Marino BJ, Musher DM (2003) Clostridium difficile infection in patients with unexplained leucocytosis. Am J Med 115:543–546

    PubMed  Google Scholar 

  66. Wanahita A, Goldsmith EA, Musher DM (2002) Conditions associated with leucocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 34:1585–1592

    PubMed  Google Scholar 

  67. Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett JG (1995) Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 123:835–840

    CAS  PubMed  Google Scholar 

  68. Bartlett JG (1992) Antibiotic-associated diarrhoea. Clin Infect Dis 15:573–581

    CAS  PubMed  Google Scholar 

  69. McFarland LV (2005) Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 54:101–111

    CAS  PubMed  Google Scholar 

  70. Leung DY, Kelly CP, Boguniewicz M et al (1991) Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 118:633–637

    CAS  PubMed  Google Scholar 

  71. Aboudola S, Kotloff KL, Kyne L et al (2003) Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 71:1608–1610

    CAS  PubMed  Google Scholar 

  72. Kelly CP (1996) Immune response to Clostridium difficile infection. Eur J Gastroenterol Hepatol 8:1048–1053

    CAS  PubMed  Google Scholar 

  73. Fekety R, McFarland LV, Surawicz CM et al (1997) Recurrent Clostridium difficile diarrhoea: characteristics of and risk factors for patients enrolled in a prospective, randomised, double-blinded trial. Clin Infect Dis 24:324–333

    CAS  PubMed  Google Scholar 

  74. McFarland LV, Elmer GW, Surawicz CM (2002) Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97:1769–1775

    CAS  PubMed  Google Scholar 

  75. Johnson S, Schriever C, Galang M et al (2007) Interruption of recurrent Clostridium difficile-associated diarrhoea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44:846–848

    CAS  PubMed  Google Scholar 

  76. Viswanath YK, Griffiths CD (1998) The role of surgery in pseudomembranous enterocolitis. Postgrad Med J 74:216–219

    CAS  PubMed  Google Scholar 

  77. Miller MA (2007) Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 45:S122–S128

    CAS  PubMed  Google Scholar 

  78. Pépin J, Valiquette L, Alary ME et al (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–472

    PubMed  Google Scholar 

  79. Novak E, Lee JG, Seckman CE et al (1976) Unfavorable effect of atropinediphenoxylate (Lomotil) therapy in lincomycin-caused diarrhea. JAMA 235:1451–1454

    CAS  PubMed  Google Scholar 

  80. Poutanen SM, Simor AE (2004) Clostridium difficile-associated diarrhea in adults. Can Med Assoc J 171:51–58

    Google Scholar 

  81. Bouza E, Munoz P, Alonso R (2005) Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 11:S57–S64

    Google Scholar 

  82. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302–307

    CAS  PubMed  Google Scholar 

  83. Pépin J, Routhier S, Gagnon S, Brazeau I (2006) Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 42:758–764

    PubMed  Google Scholar 

  84. Louie T, Gerson M, Grimard D et al (2007) Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile associated diarrhea. 47th Interscience conference on antimicrobial agents and chemotherapy, Chicago

  85. Bouza E, Dryden M, Mohammed R et al (2008) Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea. 18th European congress of clinical microbiology and infectious diseases

  86. Pépin J, Valiquette L, Gagnon S et al (2007) Outcomes of Clostridium difficile associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 102:2781–2788

    PubMed  Google Scholar 

  87. Pépin J, Saheb N, Coulombe MA et al (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254–1260

    PubMed  Google Scholar 

  88. Wilcox MH, Howe R (1995) Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 36:673–679

    CAS  PubMed  Google Scholar 

  89. Musher DM, Aslam S, Logan N et al (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40:1586–1590

    CAS  PubMed  Google Scholar 

  90. Lahue BJ, Davidson DM (2007) Metronidazole and vancomycin outcomes for Clostridium difficile-associated diarrhoea in a US hospital database. European Conference on Clinical Microbiology and Infectious Diseases, Munich

    Google Scholar 

  91. Aas J, Ce Gessert, Bakken JS (2003) Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via nasogastric tube. Clin Infect Dis 36:580–585

    PubMed  Google Scholar 

  92. Giannasca PJ, Wary M (2004) Active and passive immunisation against Clostridium difficile diarrhoea and colitis. Vaccine 22:848–856

    CAS  PubMed  Google Scholar 

  93. Kelly CP, LaMont JT (2008) Clostridium difficile-more difficult than ever. N Engl J Med 359:1932–1940

    CAS  PubMed  Google Scholar 

  94. Tedesco FJ, Gordon D, Fortson WC (1985) Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 80:867–868

    CAS  PubMed  Google Scholar 

  95. Nelson R (2007) Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev CD004610

  96. Salcedo J, Keates S, Pothoulakis C et al (1997) Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41:366–370

    Article  CAS  PubMed  Google Scholar 

  97. Warny M, Denie C, Delmee M, Lefebvre C (1995) Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A. Acta Clin Belg 50:36–39

    CAS  PubMed  Google Scholar 

  98. Juang P, Skledar SJ, Zgheib NK et al (2007) Clinical outcomes of intravenous immunoglobulin in severe Clostridium difficile-associated diarrhoea. Am J Infect Control 35:131–137

    PubMed  Google Scholar 

  99. Pillai A, Nelson R (2008) Probiotics for treatment of Clostridium difficile associated colitis in adults. Cochrane Database Syst Rev 1:CD004611

  100. Taylor NS, Bartlett JG (1980) Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 141:92–97

    CAS  PubMed  Google Scholar 

  101. Tedesco FJ (1982) Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 77:220–221

    CAS  PubMed  Google Scholar 

  102. Hookman P, Barkin JS (2009) Clostridium difficile associated infection, diarrhoea and colitis. World J Gastroenterol 15:1554–1580

    PubMed  Google Scholar 

  103. Louie TJ, Peppe J, Watt CK et al (2006) Tolevamer, a novel non-antibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhoea. Clin Infect Dis 43:411–431

    CAS  PubMed  Google Scholar 

  104. Borody T, Warren E, Leis S, Surace R, Ashman O, Siarakas S (2004) Bacteriotherapy using faecal flora: toying with human motions. J Clin Gastroenterol 38:475–483

    PubMed  Google Scholar 

  105. Borody T, Warren E, Leis S, Surace R, Ashman O (2003) Treatment of ulcerative colitis using faecal bacteriotherapy. J Clin Gastroenterol 37:42–47

    PubMed  Google Scholar 

  106. McMaster-Baxter NL, Musher DM (2007) Clostridium difficile: recent epidemiologic findings and advances in therapy. Pharmacotherapy 27:1029–1039

    CAS  PubMed  Google Scholar 

  107. Starr J (2005) Clostridium difficile—associated diarrhoea: diagnosis and treatment. BMJ 331:498–501

    PubMed  Google Scholar 

  108. Gourevitch D, Hawkey P (2009) Clostridium difficile infection and surgery. Br J Surg 96:3–4

    CAS  PubMed  Google Scholar 

  109. Noblett SE, Welfare M, Seymour K (2009) The role of surgery in Clostridium difficile colitis. BMJ 338:1196–1200

    Google Scholar 

  110. Koss K, Clark MA, Sanders DSA, Morton D, Keighley MRB, Goh J (2005) The outcome of surgery in fulminant Clostridium difficile colitis. Col Dis 8:149–154

    Google Scholar 

  111. Synnott K, Mealy K, Merry C, Kyne L, Keane C, Quill R (1998) Timing of surgery for fulminating pseudomembranous colitis. Br J Surg 85:229–231

    CAS  PubMed  Google Scholar 

  112. Pepin J, Truc Vo T, Boutros M et al (2009) Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum 52:400–405

    PubMed  Google Scholar 

  113. Hall JF, Berger D (2008) Outcome of colectomy for colitis: a plea for early surgical management. Am J Surg 196:384–388 (Clostridium difficile)

  114. Ali SO, Welch JP, Dring RJ (2008) Early surgical intervention for fulminant pseudomembranous colitis. Am Surg 74:20–26

    PubMed  Google Scholar 

  115. Nelson RL, Glenny AM, Song F (2009) Antimicrobial prophylaxis for colorectal surgery. Cochrane Database Syst Rev 1. doi:10.1002/14651858. CD001181.pub3 (Art. No.: CD001181)

  116. Bartlett JG (2002) Clinical practice. Antibiotic-associated diarrhoea. N Engl J Med 346:1079–1084

    Google Scholar 

  117. Bulstrode NW, Bradbury AW, Barrett S et al (1997) Clostridium difficile colitis after aortic surgery. Eur J Vasc Endovasc Surg 14:217–220

    CAS  PubMed  Google Scholar 

  118. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE (2004) Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 47:1620–1626

    PubMed  Google Scholar 

  119. Ash L, Baker ME, O’Malley CM Jr, Gordon SM, Delaney CP, Obuchowski NA (2006) Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: prevalence and significance of findings. Am J Roent 186:1393–1400

    Google Scholar 

  120. Byrn JC, Maun DC, Gingol DS, Baril DT, Ozao JJ, Divino CM (2008) Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 143:150–154

    PubMed  Google Scholar 

  121. Jaber MR, Olafsson S, Fung WL, Reeves ME (2008) Clinical review of the management of fulminant Clostridium difficile infection. Am J Gastro 103:3195–3203

    Google Scholar 

  122. Gash K, Brown E, Pullyblank A (2010) Emergency subtotal colectomy for fulminant Clostridium difficile Colitis is a surgical solution considered for all patients? Ann R Coll Surg Engl 92:56–60

    CAS  PubMed  Google Scholar 

  123. Lipsett PA, Samantary DK, Tam ML, Bartlett JG, Lillemoe KD (1994) Pseudomembranous colitis: a surgical disease? Surgery 116:491–496

    CAS  PubMed  Google Scholar 

  124. Seder CW, Villalba MR Jr, Robbins J et al (2009) Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Am J Surg 197:302–330

    PubMed  Google Scholar 

  125. Issa M, Ananthakrishnan N, Binion DG (2008) Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 14:1432–1442

    PubMed  Google Scholar 

  126. Freeman HJ (2008) Recent development on the role of Clostridium difficile in inflammatory bowel disease. World J Gastroenterol 14:2794–2796

    PubMed  Google Scholar 

  127. Monaghna T, Boswell T, Mahida R (2009) Recent advances in Clostridium difficile associated diseases. Postgrad Med J 85:152–162

    Google Scholar 

  128. Ananthakrishnan AN, McGinley EL, Binion DG (2008) Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57:210–256

    Google Scholar 

  129. Stone CD (2008) Prognosis in Clostridium difficile infection complication inflammatory bowel disease. Gut 57:150–152

    PubMed  Google Scholar 

  130. Jodorkovsky D, Young Y, Abreu MT (2010) Clinical outcomes of patients with ulcerativecolitis and co-existing Clostridium difficile infection. Dig Dis Sci 55:415–420

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, Trafford Healthcare Trust, Moorside Rd, Davyhulme, Manchester, M41 5SL, UK

    B. Faris

  2. Department of Colorectal Surgery, Royal Bolton Hospital, Bolton, UK

    A. Blackmore

  3. Department of Surgical Pathology, Trafford Healthcare Trust, Moorside Rd, Davyhulme, Manchester, M41 5SL, UK

    N. Haboubi

Authors
  1. B. Faris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Blackmore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Haboubi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Haboubi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faris, B., Blackmore, A. & Haboubi, N. Review of medical and surgical management of Clostridium difficile infection. Tech Coloproctol 14, 97–105 (2010). https://doi.org/10.1007/s10151-010-0574-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10151-010-0574-3

Keywords

Search

Navigation